KRAS and neoplasm: Such precision-driven approaches may exploit signals that tip the macrophage balance toward an M1-like state, thereby bolstering tumor-directed cytotoxicity, or disrupt KRAS-dependent immunosuppression in synergy with established immunotherapies (19).